Access the full text.
Sign up today, get DeepDyve free for 14 days.
D. Cutlip, S. Windecker, R. Mehran, A. Boam, D. Cohen, G. Es, P. Steg, M. Morel, L. Mauri, P. Vranckx, E. Mcfadden, A. Lansky, M. Hamon, M. Krucoff, P. Serruys (2007)
Clinical End Points in Coronary Stent Trials: A Case for Standardized DefinitionsCirculation, 115
B. Chevalier, S. Silber, Seung‐Jung Park, Eulogio García, G. Schuler, H. Suryapranata, J. Koolen, K. Hauptmann, W. Wijns, M. Morice, D. Carrié, G. Es, H. Nagai, Danny Detiege, D. Paunovic, P. Serruys (2009)
Randomized Comparison of the Nobori Biolimus A9-Eluting Coronary Stent With the Taxus Liberté Paclitaxel-Eluting Coronary Stent in Patients With Stenosis in Native Coronary Arteries: The NOBORI 1 Trial—Phase 2Circulation: Cardiovascular Interventions, 2
G. Danzi, B. Chevalier, P. Urban, F. Fath-ordoubadi, D. Carrié, M. Wiemer, A. Serra, W. Wijns, P. Kala, A. Stabile, J. Ruigómez, D. Sagic, Peep Laanmets, G. Strupp, N. West, D. Paunovic (2012)
Clinical performance of a drug-eluting stent with a biodegradable polymer in an unselected patient population: the NOBORI 2 study.EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, 8 1
Moris (2009)
Embolic protection devices in saphenous percutaneous interventionEuroIntervention, 5
E. Brilakis, Christopher Lichtenwalter, James Lemos, Michele Roesle, O. Obel, D. Haagen, Bilal Saeed, C. Gadiparthi, J. Bissett, R. Sachdeva, V. Voudris, Panagiotis Karyofillis, B. Kar, J. Rossen, P. Fasseas, P. Berger, S. Banerjee (2009)
Clinical ResearchInterventional CardiologyA Randomized Controlled Trial of a Paclitaxel-Eluting Stent Versus a Similar Bare-Metal Stent in Saphenous Vein Graft Lesions: The SOS (Stenting Of Saphenous Vein Grafts) TrialJournal of the American College of Cardiology, 53
Michael Lee, Seung‐Jung Park, D. Kandzari, A. Kirtane, W. Fearon, E. Brilakis, P. Vermeersch, Young-Hak Kim, R. Waksman, J. Mehilli, L. Mauri, G. Stone (2011)
Saphenous vein graft intervention.JACC. Cardiovascular interventions, 4 8
D. Ko, M. Chiu, Helen Guo, P. Austin, R. Goeree, E. Cohen, M. Labinaz, J. Tu (2009)
Safety and effectiveness of drug-eluting and bare-metal stents for patients with off- and on-label indications.Journal of the American College of Cardiology, 53 19
S. Windecker, P. Serruys, Simon Wandel, P. Buszman, Stanisław Trznadel, A. Linke, K. Lenk, T. Ischinger, V. Klauss, F. Eberli, R. Corti, W. Wijns, M. Morice, C. Mario, S. Davies, R. Geuns, P. Eerdmans, G. Es, B. Meier, P. Jüni (2008)
Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trialThe Lancet, 372
J. Rodés‐Cabau, O. Bertrand, É. Larose, J. Dery, S. Rinfret, R. Bagur, G. Proulx, C. Nguyen, M. Côté, Marie-Claude Landcop, Jean-Rock Boudreault, J. Rouleau, L. Roy, O. Gleeton, G. Barbeau, B. Noël, J. Courtis, G. Dagenais, J. Despres, R. Delarochelliére (2009)
Comparison of Plaque Sealing With Paclitaxel-Eluting Stents Versus Medical Therapy for the Treatment of Moderate Nonsignificant Saphenous Vein Graft Lesions: The Moderate VEin Graft LEsion Stenting With the Taxus Stent and Intravascular Ultrasound (VELETI) Pilot TrialCirculation, 120
P. Vermeersch, P. Agostoni, S. Verheye, P. Heuvel, C. Convens, F. Branden, G. Langenhove (2007)
Increased late mortality after sirolimus-eluting stents versus bare-metal stents in diseased saphenous vein grafts: results from the randomized DELAYED RRISC Trial.Journal of the American College of Cardiology, 50 3
Matthew Wiisanen, A. Abdel-Latif, D. Mukherjee, K. Ziada (2010)
Drug-eluting stents versus bare-metal stents in saphenous vein graft interventions: a systematic review and meta-analysis.JACC. Cardiovascular interventions, 3 12
G. Danzi, B. Chevalier, M. Ostojić, M. Hamilos, W. Wijns (2010)
Nobori™ drug eluting stent system: clinical evidence update.Minerva cardioangiologica, 58 5
P. Vermeersch, P. Agostoni, S. Verheye, P. Heuvel, C. Convens, N. Bruining, F. Branden, G. Langenhove (2006)
Randomized double-blind comparison of sirolimus-eluting stent versus bare-metal stent implantation in diseased saphenous vein grafts: six-month angiographic, intravascular ultrasound, and clinical follow-up of the RRISC Trial.Journal of the American College of Cardiology, 48 12
R. Wessely, V. Andrés (2012)
Limus is not limus--a proposal to adjust terminology in the context of drug-eluting stents.Journal of cardiovascular pharmacology, 59 5
E. Christiansen, L. Jensen, P. Thayssen, H. Tilsted, L. Krusell, K. Hansen, A. Kaltoft, M. Maeng, S. Kristensen, H. Bøtker, C. Terkelsen, A. Villadsen, J. Ravkilde, J. Aarøe, M. Madsen, L. Thuesen, J. Lassen (2013)
Biolimus-eluting biodegradable polymer-coated stent versus durable polymer-coated sirolimus-eluting stent in unselected patients receiving percutaneous coronary intervention (SORT OUT V): a randomised non-inferiority trialThe Lancet, 381
R. Wessely, A. Schömig, A. Kastrati (2006)
Sirolimus and Paclitaxel on polymer-based drug-eluting stents: similar but different.Journal of the American College of Cardiology, 47 4
William D'Hoore, C. Sicotte, Charles Tilquin (1993)
Risk Adjustment in Outcome Assessment: the Charlson Comorbidity IndexMethods of Information in Medicine, 32
Michael Lee, Tae Yang, D. Kandzari, J. Tobis, Hsini Liao, E. Mahmud (2010)
Comparison by meta-analysis of drug-eluting stents and bare metal stents for saphenous vein graft intervention.The American journal of cardiology, 105 8
H. Beusekom, F. Saia, J. Zindler, P. Lemos, Stijn Hoor, Maarten Leeuwen, P. Feijter, P. Serruys, W. Giessen (2007)
Drug-eluting stents show delayed healing: paclitaxel more pronounced than sirolimus.European heart journal, 28 8
E. Navarese, Jacek Kubica, Jacek Kubica, F. Castriota, C. Gibson, G. Luca, A. Buffon, L. Bolognese, M. Margheri, F. Andreotti, C. Mario, S. Servi (2011)
Safety and efficacy of biodegradable vs. durable polymer drug-eluting stents: evidence from a meta-analysis of randomised trials.EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, 7 8
A. Kirtane, Anuj Gupta, S. Iyengar, J. Moses, M. Leon, R. Applegate, B. Brodie, E. Hannan, K. Harjai, L. Jensen, Seung‐Jung Park, R. Perry, Michael Racz, F. Saia, J. Tu, R. Waksman, A. Lansky, R. Mehran, G. Stone (2009)
Safety and Efficacy of Drug-Eluting and Bare Metal Stents: Comprehensive Meta-Analysis of Randomized Trials and Observational StudiesCirculation, 119
P. Smits, S. Hofma, M. Togni, N. Vázquez, M. Valdés, V. Voudris, T. Slagboom, Jean-Jaques Goy, A. Vuillomenet, A. Serra, R. Nouche, P. Heijer, M. Ent (2013)
Abluminal biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent (COMPARE II): a randomised, controlled, non-inferiority trialThe Lancet, 381
G. Stefanini, R. Byrne, P. Serruys, Antoinette Waha, B. Meier, S. Massberg, P. Jüni, A. Schömig, S. Windecker, A. Kastrati (2012)
Biodegradable polymer drug-eluting stents reduce the risk of stent thrombosis at 4 years in patients undergoing percutaneous coronary intervention: a pooled analysis of individual patient data from the ISAR-TEST 3, ISAR-TEST 4, and LEADERS randomized trials.European heart journal, 33 10
P. Wenaweser, J. Daemen, M. Zwahlen, R. Domburg, P. Jüni, S. Vaina, G. Hellige, K. Tsuchida, Cyrill Morger, E. Boersma, N. Kukreja, B. Meier, P. Serruys, S. Windecker (2008)
Incidence and correlates of drug-eluting stent thrombosis in routine clinical practice. 4-year results from a large 2-institutional cohort study.Journal of the American College of Cardiology, 52 14
G. Luca, M. Dirksen, C. Spaulding, H. Kelbaek, M. Schalij, L. Thuesen, Bas Hoeven, M. Vink, C. Kaiser, C. Musto, T. Chechi, G. Spaziani, L. Llera, V. Pasceri, E. Lorenzo, R. Violini, G. Cortese, H. Suryapranata, G. Stone (2012)
Drug-eluting vs bare-metal stents in primary angioplasty: a pooled patient-level meta-analysis of randomized trials.Archives of internal medicine, 172 8
Background To date, no published data are available regarding long‐term follow‐up of new generation DES implanted in coronary artery bypass graft (CABG) lesions. Objectives To assess the long‐term clinical outcome of patients receiving the new generation Biolimus A9‐coated drug‐eluting stent (DES) with biodegradable polymer in saphenous vein grafts (SVG). Methods Three thousand sixty‐seven patients were included in the NOBORI 2 registry: 71 patients with a total of 117 lesions received at least 1 biolimus A9 DES in SVG lesions and 2,959 patients received percutaneous coronary intervention in other lesions. Clinical follow‐up was performed at 1, 6, and 12 months, and annually up to 3 years. Results Compared to the non‐CABG group, patients with CABG lesions were older (P < 0.001), had a higher Charlson Comorbidity Index (P = 0.004), and presented more often with acute coronary syndrome (P = 0.02). At 3‐year follow‐up, cardiac death occurred in 9.7% versus 2.1% (P < 0.001), myocardial infarction (MI) in 8.3% versus 3.0% (P = 0.02), target lesion failure in 13.9% versus 6.4% (P = 0.03), and major adverse cardiac event in 18.1% versus 8.6% (P = 0.01). No differences were observed in TV‐MI and TLR, nor stent thrombosis (ST) which was generally low in both groups (1.4% vs 0.8%, P = NS). Conclusion Albeit 3‐year outcomes were less favorable in the CABG group, the higher cardiac mortality was apparently not driven by ST, target vessel MI, or TLR, but is likely due to advanced disease and age as well as comorbidity. The low TLR rate as well as the absence of late and very late ST suggest that BES are safe and effective for the treatment of CABG lesions. (J Interven Cardiol 2013;26:425‐433)
Journal of Interventional Cardiology – Wiley
Published: Oct 1, 2013
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.